Trial Profile
Randomised Placebo-Controlled Single Blind Study to Investigate Single Ascending Doses of GNbAC1 in Multiple Sclerosis Patients Followed by Open-label Extension With Repeated Doses of GNbAC1
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2015
Price :
$35
*
At a glance
- Drugs Temelimab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors GeNeuro
- 03 Sep 2014 Results published in the Media Release.
- 14 Mar 2014 On 4 Nov 2013, GeNeuro reported the trial is completed however, ClinicalTrials.gov record was updated on 27 Jan 2014 to report the status as active, no longer recruiting with an estimated primary completion date of Feb 2014.
- 04 Nov 2013 Top-line results reported in a GeNeuro media release.